Other cookies are configurable.
Supply continuity and business resilience for a global pharmaceutical manufacturer
Regulated supply assurance, ISO 22301 aligned governance and disruption preparedness where continuity is inseparable from patient safety.
Business context: continuity is inseparable from patient safety
Disruption in pharmaceutical environments is measured in patient safety, public trust and regulatory accountability, not only financial impact:
- Strict regulatory oversight of manufacturing and distribution.
- Dependence on specialised suppliers and controlled materials.
- Cold chain logistics and time sensitive delivery obligations.
- High reputational exposure during disruption events.
- Rising cyber risk across production and laboratory systems, escalating into product availability interruption and audit failure.
The situation
The organisation operated complex multinational manufacturing and distribution networks with fragmented resilience maturity:
- Inconsistent continuity maturity between production sites.
- Supplier disruption exposure not systematically measured.
- Recovery priorities differing across business units and geographies.
- Limited integration between cyber incident response and manufacturing continuity.
- No unified governance connecting audit expectations and operational recovery capability.
How the engagement was built
01Critical product and manufacturing continuity prioritisation
With leadership we defined what must remain protected under all conditions: essential manufacturing lines and controlled environments, quality critical laboratory functions, release and batch certification, regulated distribution.
02Supplier and regulated supply chain assurance
Systematic measurement of supplier disruption exposure across controlled materials and logistics, with continuity strategies for the dependencies that protect patient critical supply.
03Cyber integrated manufacturing continuity
Cyber disruption of production and laboratory systems integrated into continuity sequencing and crisis command governance, not handled as a separate IT event.
04Governance, audit readiness and exercising
ISO 22301 aligned governance connecting audit expectations with real recovery capability, proven through leadership exercises.
What programmes of this maturity deliver
Consistent with the firm's experience across the sector, high maturity programmes of this kind typically achieve:
- Stronger supplier continuity oversight.
- Improved audit and regulatory readiness.
- Increased assurance of uninterrupted patient critical supply.
How does ISO 22301 apply to pharmaceutical organisations?
It ensures critical production, batch release and distribution functions are prioritised, recovery objectives are defined and continuity capability is auditable under regulatory scrutiny.
Why is continuity in pharma different from other industries?
Pharmaceutical disruption impacts patient safety and regulatory compliance. Recovery strategies must protect product integrity, controlled environments and healthcare supply obligations.
How do cyber incidents affect pharmaceutical continuity?
Cyber disruption increasingly impacts manufacturing and laboratory systems. Effective resilience integrates cyber recovery into regulated production continuity and crisis command governance.
Put this capability behind your operations.
A confidential conversation with a senior practitioner who has delivered in your sector. We respond within 24 hours.
Book a consultation